Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor

European Heart Journal, Supplement

Volumn 3, Issue SUPPL.5, 2001, Pages

  Stein, E ^a  

^a Pharmaceutical Product Development   (United States)

Author keywords

Cholesterol absorption inhibitor; Ezetimibe; Hypercholesterolaemia; Pharmacokinetic pharmacodynamic; Phase II studies; Statins

Indexed keywords

EID: 0000801934     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(01)90107-5     Document Type: Article

References (11)

1. van Heek M, France CF, Compton DS et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther 1997; 283: 157-63.
2. van Heek M, Farley C, Compton DS et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 2000; 129: 1748-54.
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). J Am Med Assoc 1993; 269: 3015-23.
4. Bays H, Drehobl M, Rosenblatt S et al. Low-density lipoprotein cholesterol reduction by SCH 58235 (ezetimibe), a novel inhibitor of cholesterol absorption, in 243 hypercholesterolemic subjects: results of a dose-response study (Abstr). Atherosclerosis 2000; 151: 133.
5. Lipka LJ, LeBeaut AP, Veltri EP et al. Reduction of LDL-cholesterol and elevation of HDL-cholesterol in subjects with primary hypercholesterolemia by ezetimibe (SCH 58235): pooled analysis of two phase II studies (Abstr). J Am Coll Cardiol 2000; 35 (Suppl 2A): 257A.
6. Kosoglou T, Meyer I, Musiol B et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor SCH 58235 and simvastatin (Abstr). Atherosclerosis 2000; 151: 135.
7. Statkevich P, Zhu Y, Kosoglou T et al. Ezetimibe (SCH 58235) does not affect the pharmacokinetics of simvastatin (Abstr). Clin Pharmacol Ther 2000; 67: 146.
8. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341: 498-511.
9. Kosoglou T, Meyer I, Musiol B et al. Coadministration of simvastatin and ezetimibe leads to significant reduction in LDL-cholesterol (Abstr). Third International Congress on Coronary Artery Disease - from Prevention to Intervention; Lyon, France, October 2-5, 2000: 71.
10. Kosoglou T, Meyer I, Cutler DL et al. Pharmacodynamic interaction between the selective cholesterol absorption inhibitor ezetimibe and lovastatin (Abstr). Third International Congress on Coronary Artery Disease - from Prevention to Intervention; Lyon, France, October 2-5, 2000: 101.
11. Zhu Y, Statkevich P, Kosoglou T et al. Effect of ezetimibe (SCH 58235) on the activity of drug metabolizing enzymes in vivo (Abstr). Clin Pharmacol Ther 2000; 67: 152.